healthcare supply chain

The maker of syringes, needles and infusion pumps will expand U.S. output and use American steel for needles in exchange for conditional Section 232 relief. Hospital and health system buyers should expect more deals like it.

The Upper Merion site will combine commercial biologics production, a pilot plant and quality labs, part of GSK's $30 billion U.S. pledge through 2030. Construction starts in 2027, so supply effects are years out.